There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines nejm.org/doi/full/10.1056/NE…

ASCO this year has 5,000 abstracts. But maybe 24 will actually change practice. This is that map. (ERRATA: this plot fixes an error on VICTORIA which reflected incorrect data, thnx @Dr_RShatsky) Map spans 12 disease areas, 24 critical readouts, 5 plenaries & 2 confirmed misses already on the board. Few things jump out immediately: ▫️Pancreatic cancer gets the headline. Daraxonrasib: 13.2 vs 6.7 months. ▫️Sarcoma gets a plenary because public science funded what pharma would not. ▫️Lung cancer remains the most crowded battlefield in oncology: RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR. By next week, some of these cells will become new standards of care. This is your cheat sheet to keep score in real time. - - - - - Sources: @asco @OncLive @CancerNetwrk via @Jori_health - - - - -

The biggest cancer results from ASCO this week, ranked by how much they change a patient’s odds. 1. Colon cancer (BRAF-mutant): the combination doubled survival. Median 30.3 months vs 15.1 on the old standard. BREAKWATER. New standard of care. 2. Lung cancer (ALK ): five years out, 60% of patients on lorlatinib still hadn’t progressed. On the old drug, 8%. CROWN. 3. Lung cancer (EGFR ): amivantamab plus lazertinib cut the risk of death 25% vs the previous best pill. MARIPOSA. 4. Breast cancer (PIK3CA-mutant): gedatolisib hit its primary survival mark, beating the current targeted drug. VIKTORIA-1. Full numbers drop this week. 5. Prostate cancer (high-risk): apalutamide before surgery, the plenary headline. First efficacy readout lands this week. 6. Breast cancer (ER ): SERENA-6, the blood-test-guided drug switch, reports next. Five years ago, half of these patients had almost nothing.

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

That sound you hear is the culture of American surgery breaking—in preparation to be rebuilt for the better. More healthy, more vulnerable, and more human. Thank you to @lubitz_carrie for the most important Presidential address I’ve had the opportunity to hear. #ASC2023

In a new @womenspowergap report, @RutgersU was identified as a national leader among higher education institutions for the representation of women in leadership roles, ranking 13th out of 130 universities.

I had a great evening exploring the new innovations in breast surgery. Thank you @ASBrS for the opportunity to showcase my research regarding PALB2, CHEK2, and ATM gene mutations. #ASBrS2022

Excited to be attending #ASBrS2022

Honored to have our work on the interplay of age and frailty in predicting failure-to-rescue after GI cancer surgery included at #SSO2022. Thanks to excellent mentorship by Dr. David August and other great minds @CDavisMD @MariaFencer @HenryPittMD @RutgersCancer @RWJMS